September 2nd, 2025

Acuitas Therapeutics Announces Oral Presentations at the 2025 Alliance for mRNA Medicines' Annual Meeting

Vancouver, B.C. – Acuitas Therapeutics, a global leader in lipid nanoparticle (LNP) delivery systems for the acceleration of partners' clinical development, today announced two upcoming presentations showcasing its LNP delivery platform for personalized gene-editing therapies and its advances in delivery mechanisms. These will be presented at the 2025 Alliance for mRNA Medicines (AMM) Advancements in mRNA Science, Commercialization, Education, and Novel Technologies (ASCENT) Annual Meeting from September 16-18 in Coronado, California.

Acuitas will be sharing insights on panels about the future of mRNA in Gene Editing and Rare Disease and mRNA delivery innovation. These studies reinforce Acuitas' commitment to advancing LNP technology through robust scientific validation and to expanding its role in next-generation therapeutic solutions.

Presentation Details:

Fireside chat: What's Next After Baby KJ? The Future of mRNA in Gene Editing and Rare Disease

- Presenter: Rob Leone, Sr. Director, Chemistry, Manufacturing & Controls
- Date: **September 16th, 2025**

mRNA Delivery Innovation Panel

- Presenter: Sean Semple, Vice President, Preclinical Research
- Date: **September 18th, 2025**

More information about the conference can be found on AMM's website.

About Acuitas Therapeutics

Acuitas Therapeutics, Inc. is a Vancouver-based company focused on developing and optimizing lipid nanoparticle (LNP) delivery systems for nucleic acid based therapeutics. They collaborate with pharmaceutical and biotech companies, academic researchers, and global health organizations to advance a broad range of medicines for a variety of diseases.

Acuitas' clinically validated LNP technology has had a profound global impact – most notably enabling the Pfizer-BioNTech COVID-19 vaccine, **COMIRNATY®**, which has protected billions of people in more than 180 countries. The technology also enables **ONPATTRO®** by Alnylam

Pharmaceuticals, the first FDA-approved RNAi therapeutic for treating the rare and fatal disease transthyretin amyloidosis. More recently, Acuitas' LNP technology has delivered other groundbreaking firsts: the **first in-human proof of concept** for genome base editing and the **first personalized CRISPR therapy**.

Today, they are advancing next-generation LNP to support a variety of therapeutic modalities. This includes targeted LNP for extrahepatic and *in vivo* CAR-T cell therapies, epigenetic medicines to modulate gene expression without altering DNA, multivalent vaccines for infectious diseases — such as malaria, HIV/AIDS, and tuberculosis — as well as oncology vaccines, including personalized cancer vaccines.

For more information, visit www.acuitastx.com.

-END-